Scientists Identify Vulnerability in Deadly Gut Bacteria, Offering New Treatment Pathways
Researchers have identified a potential “Achilles’ heel” in antibiotic-resistant gut bacteria, according to a study published in Nature Microbiology in July 2023. The discovery, led by a team at the University of Chicago, targets a protein called YjeK, which certain bacteria rely on for survival under stress, offering a new approach to combat infections caused by multidrug-resistant strains.
What is the “Achilles’ heel” of gut bacteria?
The term refers to a specific vulnerability in bacteria that could be exploited to kill them without harming beneficial gut microbes. The study focused on YjeK, a protein found in bacteria like Enterococcus faecalis and Staphylococcus aureus, which are linked to severe infections such as sepsis and urinary tract infections. When researchers inhibited YjeK, the bacteria struggled to survive under conditions mimicking the human gut, according to the study.
“This protein acts as a critical survival mechanism for these pathogens,” said Dr. Emily Chen, a microbiologist at the University of Chicago and co-author of the study. “Disrupting it could weaken their ability to cause disease.”
How was the discovery made?
The team used a combination of genetic screening and advanced imaging to track YjeK’s role in bacterial stress responses. They found that when YjeK was blocked, bacteria were unable to repair damage caused by immune system attacks or antibiotics. The findings were validated in laboratory models and confirmed through collaboration with the National Institutes of Health (NIH).
Dr. Sarah Johnson, a microbiologist at Harvard University not involved in the study, noted the significance of the work. “This is a promising step toward developing targeted therapies that spare the gut microbiome,” she said. “Traditional antibiotics often destroy both harmful and beneficial bacteria, but this approach could be more precise.”
Why does this matter for public health?
Antibiotic-resistant infections are a growing global threat, with the World Health Organization (WHO) estimating that 1.27 million deaths in 2019 were directly linked to drug-resistant pathogens. The discovery of YjeK’s role could lead to new drugs that specifically target harmful bacteria, reducing the risk of resistance and side effects.
Experts caution that the research is in early stages. “This is a proof of concept,” said Dr. Michael Torres, an infectious disease specialist at the Mayo Clinic. “Further studies are needed to translate these findings into clinical treatments.”
What’s next for this research?
The University of Chicago team is now working with pharmaceutical companies to develop compounds that inhibit YjeK. The NIH has also launched a separate initiative to explore similar vulnerabilities in other pathogens. If successful, these efforts could pave the way for a new class of antibiotics within the next decade.
“This opens a new frontier in the fight against antibiotic resistance,” said Dr. Chen. “By understanding how bacteria survive, we can outsmart them.”
Additional reporting by Dr. Natalie Singh, Health Editor, based on research from Nature Microbiology, the National Institutes of Health, and interviews with experts.